Quick Answer
Serina Therapeutics, Inc. reported Stockholders Equity of -$37.0 thousand for the year ending 2025.
- Serina Therapeutics, Inc. showed a decrease of -105.8% in Stockholders Equity from 2024 to 2025.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: $7.45 million | Q1 2019: $9.32 million | Q2 2019: $6.75 million | Q3 2019: $4.34 million | Q1 2020: -$739.0 thousand | Q2 2020: -$2.44 million | Q3 2020: -$3.65 million | Q1 2021: -$6.06 million | Q2 2021: -$8.25 million | Q3 2021: -$9.94 million | Q1 2022: -$11.55 million | Q2 2022: -$13.22 million | Q3 2022: -$15.10 million | Q4 2022: -$37.78 million | Q1 2023: -$36.12 million | Q2 2023: -$22.18 million | Q3 2023: -$27.54 million | Q1 2024: -$4.31 million | Q2 2024: -$16.36 million | Q3 2024: -$13.77 million | Q1 2025: $1.70 million | Q2 2025: $1.80 million | Q3 2025: $1.76 million.
- Over the full 9 years of available data (2017 to 2025), Serina Therapeutics, Inc.'s Stockholders Equity has declined by 100.5%.
- Historical annual values: Fiscal year 2025: -$37.0 thousand | Fiscal year 2024: $641.0 thousand | Fiscal year 2023: -$32.29 million | Fiscal year 2022: -$17.21 million | Fiscal year 2021: -$11.83 million | Fiscal year 2020: -$5.12 million | Fiscal year 2019: $2.22 million | Fiscal year 2018: $7.45 million | Fiscal year 2017: $7.28 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: